Published in J Cell Mol Med on December 05, 2007
miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA (2013) 1.25
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20
Stress and breast cancer: from epidemiology to molecular biology. Breast Cancer Res (2011) 1.16
Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res (2013) 0.98
Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer (2012) 0.89
Genomic and non-genomic effects of glucocorticoids: implications for breast cancer. Int J Clin Exp Pathol (2015) 0.85
Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors. Epigenetics (2014) 0.84
Identification and functional annotation of genome-wide ER-regulated genes in breast cancer based on ChIP-Seq data. Comput Math Methods Med (2012) 0.80
Antiproliferative effect of dexamethasone in the MCF-7 breast cancer cell line. Mol Med Rep (2015) 0.80
Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol (2017) 0.75
The Pathophysiologic Role of Disrupted Circadian and Neuroendocrine Rhythms in Breast Carcinogenesis. Endocr Rev (2016) 0.75
Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments. Oncoscience (2016) 0.75
The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-κB Signaling. Mar Drugs (2017) 0.75
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 11.26
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature (1999) 10.48
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem (1995) 8.32
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer (1989) 8.07
Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature (1986) 7.81
Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev (1999) 7.42
Acetylation and deacetylation of non-histone proteins. Gene (2005) 6.87
MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell (1993) 6.55
DNA binding of the glucocorticoid receptor is not essential for survival. Cell (1998) 6.40
Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol (1998) 6.27
How MAP kinases are regulated. J Biol Chem (1995) 6.04
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 6.00
Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol (2001) 5.78
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell (2002) 5.61
MAPKs: new JNK expands the group. Trends Biochem Sci (1994) 4.10
Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer (2003) 3.96
EGF receptor. Int J Biochem Cell Biol (1999) 3.91
Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res (2003) 3.71
Steroid hormone receptors compete for factors that mediate their enhancer function. Cell (1989) 3.50
The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev (2003) 3.40
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat (2006) 2.89
Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev (2002) 2.89
Structural and functional characteristics of S1P receptors. J Cell Biochem (2004) 2.75
The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev (1998) 2.58
Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol (1998) 2.54
Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis. Oncogene (2001) 2.51
Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol (2004) 2.44
Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem (2002) 2.42
Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell (2005) 2.39
Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J (2001) 2.39
Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res (2004) 2.35
p53 and breast cancer, an update. Endocr Relat Cancer (2006) 2.27
Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J (2002) 2.26
Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest (1995) 2.20
Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol (2002) 2.10
Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Sci STKE (2005) 2.03
Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci (2004) 1.97
Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J Biol Chem (1995) 1.96
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol (2006) 1.96
Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo. J Biol Chem (2002) 1.95
Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A (1995) 1.94
Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther (2006) 1.92
Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem (2001) 1.89
Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol (1997) 1.88
Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J (1995) 1.84
Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem (2005) 1.81
The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem (1999) 1.76
The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr (2000) 1.75
Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst (2000) 1.74
Tissue glucocorticoid resistance/hypersensitivity syndromes. J Steroid Biochem Mol Biol (2003) 1.74
Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem (2001) 1.74
Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem (2002) 1.72
Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res (1988) 1.70
Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci U S A (1998) 1.66
Molecular mechanism of TNF signaling and beyond. Cell Res (2005) 1.66
Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat (1995) 1.63
Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Mol Cell Biol (1993) 1.62
Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev (1996) 1.60
Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology (2006) 1.58
Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem (2004) 1.55
p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol (2005) 1.52
Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol (2006) 1.46
The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res (2000) 1.45
Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2. J Biol Chem (2002) 1.44
Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol (2002) 1.43
Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol (2003) 1.42
Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol (2002) 1.42
Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett (2003) 1.39
Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol (2004) 1.38
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem (2003) 1.37
G protein beta interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. J Cell Biol (2005) 1.37
Growth factors in breast cancer. Endocr Rev (1995) 1.37
Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol (2006) 1.36
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res (1979) 1.35
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene (2002) 1.34
Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol (1995) 1.32
Expression and function of interleukin-6 in epithelial cells. J Cell Biochem (1991) 1.32
Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol Endocrinol (1997) 1.31
The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim Biophys Acta (2005) 1.29
Site-directed mutagenesis of nm23-H1. Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells. J Biol Chem (1996) 1.28
A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol (2002) 1.26
Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry (1999) 1.26
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol (2006) 1.25
Expression and subcellular distribution of the beta-isoform of the human glucocorticoid receptor. Endocrinology (1997) 1.23
Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci U S A (1994) 1.23
Selective activation of the glucocorticoid receptor by steroid antagonists in human breast cancer and osteosarcoma cells. J Biol Chem (2000) 1.22
Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech Dev (2000) 1.21
Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res (2000) 1.21
Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res (1996) 1.21
Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol (2005) 1.20
Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol (2002) 1.20
Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer (1999) 1.16
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov (2007) 2.67
Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol (2002) 2.04
Molecular medicine: a lifetime of learning, teaching and caring. Trends Mol Med (2005) 2.02
Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res (2007) 1.79
Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med (2011) 1.73
Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance? Int J Colorectal Dis (2009) 1.51
p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab Invest (2005) 1.49
Colorectal cancer stem cells. Stem Cells (2012) 1.47
Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med (2006) 1.44
The alpha2B adrenergic receptor deletion/insertion polymorphism in morbid obesity. Clin Auton Res (2003) 1.43
Different Prognostic Significance of Cardiac Troponin at Presentation and Peak Cardiac Troponin in Patients with Non-ST Segment Elevation Myocardial Infarction. Cardiology (2016) 1.40
Mechanotransduction in osteoblast regulation and bone disease. Trends Mol Med (2009) 1.32
Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice. Diabetes (2011) 1.30
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol (2009) 1.27
Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab (2007) 1.26
TGF-beta signalling in colon carcinogenesis. Cancer Lett (2011) 1.26
Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis. Cell Res (2007) 1.24
Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol (2004) 1.20
Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A (2012) 1.19
The bone-specific transcriptional regulator Cbfa1 is a target of mechanical signals in osteoblastic cells. J Biol Chem (2002) 1.18
Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease. Neuromolecular Med (2014) 1.13
Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol (2012) 1.10
Runx2: of bone and stretch. Int J Biochem Cell Biol (2007) 1.09
Role of vitamin D in atherosclerosis. Circulation (2013) 1.07
p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. EMBO J (2003) 1.06
Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Hum Mol Genet (2008) 1.05
Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs (2012) 1.04
PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol (2005) 1.04
The NF-κB signalling pathway in osteoarthritis. Int J Biochem Cell Biol (2013) 1.04
Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proc Natl Acad Sci U S A (2010) 1.03
Signaling networks and transcription factors regulating mechanotransduction in bone. Bioessays (2009) 1.03
Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab (2011) 1.02
DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl) (2013) 1.02
Hydrogen bonds in protein-DNA complexes: where geometry meets plasticity. Biochimie (2007) 1.01
FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis (2012) 1.01
The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer (2013) 1.00
Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab (2012) 1.00
Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev (2010) 0.99
NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis (2006) 0.99
Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med (2005) 0.98
High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med (2009) 0.98
Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol (2006) 0.98
Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med (2008) 0.97
The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol (2011) 0.96
Colon carcinogenesis: Learning from NF-kappaB and AP-1. Int J Biochem Cell Biol (2010) 0.96
Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl) (2007) 0.96
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol (2006) 0.95
Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol (2004) 0.95
Renal dysgenesis and KAL1 gene defects in patients with sporadic Kallmann syndrome. Fertil Steril (2007) 0.95
NF-κB in colorectal cancer. J Mol Med (Berl) (2013) 0.95
Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des (2011) 0.94
Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. Int J Biochem Cell Biol (2012) 0.94
Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem (2012) 0.93
Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) (2008) 0.93
Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J Bone Miner Metab (2010) 0.93
SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat (2007) 0.93
Simvastatin lowers reactive oxygen species level by Nrf2 activation via PI3K/Akt pathway. Biochem Biophys Res Commun (2010) 0.92
Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs (2010) 0.92
Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer (2009) 0.92
CHOP-dependent regulation of p21/waf1 during ER stress. Cell Physiol Biochem (2010) 0.92
Involvement of the p38 MAPK-NF-kappaB signal transduction pathway and COX-2 in the pathobiology of meniscus degeneration in humans. Mol Med (2008) 0.91
Simvastatin activates Keap1/Nrf2 signaling in rat liver. J Mol Med (Berl) (2008) 0.91
Expression of ERalpha, ERbeta and co-regulator PELP1/MNAR in colorectal cancer: prognostic significance and clinicopathologic correlations. Cell Oncol (2009) 0.90
Fatty acids derived from royal jelly are modulators of estrogen receptor functions. PLoS One (2010) 0.90
Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer (2002) 0.90
P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int J Cancer (2008) 0.90
Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol (2007) 0.90
The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther (2007) 0.90
Serum leptin, adiponectin and tumor necrosis factor-α in hyperlipidemic rats with/without concomitant diabetes mellitus. Mol Med (2010) 0.89
Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol (2007) 0.89
Shear stress, protein kinases and atherosclerosis. Curr Med Chem (2007) 0.89
Expression of integrin-linked kinase and its binding partners in chondrosarcoma: association with prognostic significance. Eur J Cancer (2008) 0.89
Glucocorticoid receptor signaling in bone cells. Trends Mol Med (2012) 0.89
Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol (2009) 0.89
Functional significance of the thyrotropin receptor germline polymorphism D727E. Biochem Biophys Res Commun (2003) 0.89
Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy. Curr Med Chem (2008) 0.88
Seeing the future of cancer-associated transcription factor drug targets. JAMA (2011) 0.88
Effects of Ω-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study. Int J Cardiol (2011) 0.88
p53 antagonizes the unfolded protein response and inhibits ground glass hepatocyte development during endoplasmic reticulum stress. Exp Biol Med (Maywood) (2012) 0.88
Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol Sci (2006) 0.88
Load application induces changes in the expression levels of Sox-9, FGFR-3 and VEGF in condylar chondrocytes. FEBS Lett (2007) 0.88
Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis (2013) 0.88
EGF-R is expressed and AP-1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Cell Oncol (2007) 0.88
The activator protein-1 transcription factor in respiratory epithelium carcinogenesis. Mol Cancer Res (2007) 0.87
HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer (2007) 0.87
Pharmacogenetic principles in the Hippocratic writings. J Clin Pharmacol (2005) 0.87
Segmental bone defects: from cellular and molecular pathways to the development of novel biological treatments. J Cell Mol Med (2010) 0.87
Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. J Cell Mol Med (2010) 0.87
Effect of protein kinase inhibitors on the stretch-elicited c-Fos and c-Jun up-regulation in human PDL osteoblast-like cells. J Cell Physiol (2002) 0.86
Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer. Tumour Biol (2012) 0.86
Molecular mechanisms regulating matrix metalloproteinases. Curr Top Med Chem (2012) 0.86
Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions. Int J Biochem Cell Biol (2006) 0.86
Transcription factor therapeutics: long-shot or lodestone. Curr Med Chem (2005) 0.86
Association of sarcoidosis with endothelial function, arterial wall properties, and biomarkers of inflammation. Am J Hypertens (2011) 0.85
Biomolecular strategies of bone augmentation in spinal surgery. Trends Mol Med (2010) 0.85
Could glucose be a proaging factor? J Cell Mol Med (2008) 0.85
Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol (2012) 0.85
New therapeutic options for the metabolic syndrome: what's next? Trends Endocrinol Metab (2005) 0.85
Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opin Investig Drugs (2007) 0.85